What is LGNYZ's health score?

LIGAND PHARMACEUTICALS INC (LGNYZ) has a TradeApes health score of 58 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is LGNYZ's estimated fair value?

Based on our 5-year discounted cash flow model, LIGAND PHARMACEUTICALS INC's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is LGNYZ undervalued or overvalued?

Our model currently rates LGNYZ as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for LGNYZ... Refresh in a moment for the full analysis.

LIGAND PHARMACEUTICALS INC (LGNYZ)

Healthcare Inconclusive inconclusive mixed

Updated: 2026-06-05

TradeApes Score

Financial Strength

85 Strong

Operating Trend

50 Mixed

Relative Value

48 Mixed

Capital Allocation

30 Weak

Risk

80 Strong

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.